NASDAQ$DNLI
Denali Therapeutics Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2020 and provided business highlights.
Denali Therapeutics reported a net loss of $58.8 million for the second quarter of 2020. They entered into a collaboration agreement with Biogen on the LRRK2 program and commenced dosing of DNL310 in Hunter syndrome patients.
- Entered into a Collaboration Agreement with Biogen on LRRK2 program for Parkinson’s disease and certain transport vehicle (TV) platform-enabled programs for neurodegenerative diseases.
- Selected DNL151 to advance into late stage clinical studies in Parkinson’s disease patients.
- Commenced dosing of DNL310 in Hunter syndrome patients.
- Publication of two scientific papers describing blood-brain barrier transport vehicle delivery technology.
Headline financials
Revenue & EPS history
Denali Therapeutics · Revenue · Quarterly
$5.85M
Forward guidance
This press release contains forward-looking statements regarding Denali's progress and business plans, expectations regarding the proposed transaction with Biogen, and plans to conduct clinical development activities and commercialize products.
Tailwinds
- plans to conduct clinical development activities
- plans to commercialize products
- LRRK2 inhibitors as modifying therapy for Parkinson’s disease
- plans, timelines and expectations related to DNL151
- plans, timelines and expectations related to DNL310 and Denali’s TV technology
Headwinds
- risks related to Denali’s business and operations caused directly or indirectly by the evolving COVID-19 pandemic
- the risks that the proposed transaction with Biogen may not be completed in a timely manner or at all
- the possibility that certain closing conditions to the proposed transaction will not be satisfied, including the finalization of a definitive collaboration agreement
- risks related to obtaining the requisite regulatory approvals, including those required under antitrust laws
- risk of the occurrence of any event, change or other circumstance that could give rise to the termination of Denali’s agreements with Biogen or any of Denali’s other collaboration agreements
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-0.3%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+1.3%
Avg return
30 days after
44%
14 / 32 earnings
Positive
+19.7%
Q4 2023
Best reaction
-13.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -1.0% | -4.9% | -15.2% | |
| Q3 2025 | -3.2% | +18.1% | +34.0% | |
| Q1 2025 | +1.0% | -0.9% | +6.1% | |
| Q4 2024 | -1.5% | -15.6% | -21.8% | |
| Q3 2024 | +7.1% | +14.2% | -10.0% | |
| Q2 2024 | -10.3% | -9.7% | +0.3% | |
| Q1 2024 | +10.3% | +6.8% | +24.3% | |
| Q4 2023 | +19.7% | +23.5% | +21.5% | |
| Q3 2023 | -2.7% | -21.8% | -9.7% | |
| Q2 2023 | -5.2% | -7.6% | -7.3% | |
| Q1 2023 | +3.0% | +5.4% | +16.1% | |
| Q4 2022 | +4.8% | +7.3% | -10.9% | |
| Q3 2022 | -7.8% | -10.3% | +6.2% | |
| Q2 2022 | +4.6% | +6.6% | -17.5% | |
| Q1 2022 | -13.7% | -14.0% | -8.5% | |
| Q4 2021 | -2.8% | -7.8% | -1.9% | |
| Q3 2021 | +3.5% | -0.4% | -19.9% | |
| Q2 2021 | +3.5% | +4.6% | +6.6% | |
| Q1 2021 | -8.0% | -10.2% | +5.5% | |
| Q4 2020 | +7.5% | -5.8% | -17.2% | |
| Q3 2020 | +5.2% | +16.3% | +40.8% | |
| Q2 2020 | +6.1% | -5.4% | -2.5% | |
| Q1 2020 | -5.5% | -5.7% | +2.6% | |
| Q4 2019 | -8.6% | -10.0% | -12.5% | |
| Q3 2019 | -6.1% | -10.1% | +10.5% | |
| Q2 2019 | +0.6% | +5.4% | -4.2% | |
| Q1 2019 | -4.8% | -11.4% | -18.9% | |
| Q4 2018 | +11.7% | +12.0% | +26.4% | |
| Q3 2018 | -4.0% | -0.6% | +12.7% | |
| Q2 2018 | -0.5% | -0.7% | +17.0% | |
| Q4 2017 | -4.8% | -5.1% | +2.2% | |
| Q1 2018 | -8.8% | -8.0% | -12.4% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro